ATOS
Atossa Therapeutics, Inc. Common StockstockNASDAQ
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.03 | 2026-11-11 | -11.33% | -0.130 |
| 1M | 2.56 | 2026-10-19 | -29.69% | -0.168 |
| 3M | 2.59 | 2026-08-18 | -30.50% | -0.026 |
| 6M | 4.78 | 2026-05-18 | -62.34% | -0.235 |
| 1Y | 11.85 | 2025-11-18 | -84.81% | 0.599 |
| 2Y | 19.20 | 2024-11-18 | -90.63% | — |
| 5Y | 34.35 | 2021-11-18 | -94.76% | 1.118 |
Atossa Therapeutics, Inc. Common Stock (NASDAQ:ATOS) stock price today is $1.80, and today's volume is 44,435. ATOS is down 5.263% today. The 30 day average volume is 81,572. ATOS market cap is $17.96M with 9.98M shares outstanding.
